Dyne Therapeutics Inc Aktie News

An analyst upgraded his recommendation on the biotech. He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target.

Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one year, providing financial flexibility for late-stage trials and regulatory submissions. DYNE-101 and DYNE-251 both show promising safety and efficacy data, with potential accelerated FDA submissions...

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares.

Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter.

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day op...

Its No. 1 drug candidate did well in a clinical trial. It met both its primary and secondary endpoints.

Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript